Accueil
Explorer
nav.journalClub
Tendances
Plus
synapse
⌘+K
Langue
Français
Français
Tocilizumab Prophylaxis Following Idecabtagene Vicleucel in the Outpatient Setting in Patients with Relapsed or Refractory Multiple Myeloma | Synapse
March 3, 2026
Tocilizumab Prophylaxis Following Idecabtagene Vicleucel in the Outpatient Setting in Patients with Relapsed or Refractory Multiple Myeloma
EP
Edward Peres
Henry Ford Health System
SF
Shatha Farhan
Henry Ford Health System
JE
Josephine Emole
Henry Ford Health System
See all
Key Points
Tocilizumab prophylaxis correlates with enhanced treatment outcomes in multiple myeloma.
A significant improvement in adverse events was noted compared to historical controls.
Observational analysis shows the use of tocilizumab following idecabtagene vicleucel in an outpatient setting.
Findings may support expanded use of tocilizumab in treatment protocols for multiple myeloma.
Mark Helpful
Like
Save
Bookmark
Relay
Share
Mark Helpful
Like
Save
Bookmark
Relay
Share
Cite This Study
Copy
Peres et al. (Sun,) studied this question.
synapsesocial.com/papers/69a7603ac6e9836116a2cc24
https://doi.org/https://doi.org/10.1016/j.jtct.2025.12.278